Herantis Pharma Oyj: Manager’s Transactions - Timo Veromaa

Herantis Pharma Oyj: Manager’s Transactions - Timo Veromaa

Herantis Pharma Plc
Company release 31 May 2019 at 1:00 pm

Herantis Pharma Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Veromaa, Timo

Position: Member of the Board/Deputy member

Issuer: Herantis Pharma Oyj

LEI: 743700W4CQVYAT3WKK38

Notification type: INITIAL NOTIFICATION

Reference number: 743700W4CQVYAT3WKK38_20190529112057_3

____________________________________________

Transaction date: 2019-05-31

Venue not applicable

Instrument type: SHARE

ISIN: FI4000087861

Nature of the transaction: EXERCISE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 4,400 Unit price: .00005 EUR

Aggregated transactions

(1): Volume: 4,400 Volume weighted average price: .00005 EUR

____________________________________________

Further information:

Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225

Distribution:

Nasdaq Helsinki
Main media
www.herantis.com

About Us

Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases. These include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com

Subscribe